INCY Incyte Corp

Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary therapeutics. Its product JAKAFI, a JAK1 and JAK2 inhibitor is used for treatment of patients with intermediate or high risk myelofibrosis.

$79.99  -0.84 (-1.04%)
As of 04/09/2021 15:59:46 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Large cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/20/2001
Outstanding shares:  219,843,497
Average volume:  1,271,966
Market cap:   $17,578,686,020
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    45337C102
ISIN:        US45337C1027
Sedol:      2471950
Valuation   (See tab for details)
PE ratio:   -59.45
PB ratio:   6.72
PS ratio:   6.59
Return on equity:   -17.06%
Net income %:   -16.70%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy